Stockscreener 앱 받기
0.63
0.16%
-0.001
시간 외 거래:
.63
전일 마감가:
$0.631
열려 있는:
$0.69
하루 거래량:
14,738
Relative Volume:
0.13
시가총액:
$3.75M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-7.35%
1개월 성능:
-9.42%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.6255
$0.69
1주일 범위
$0.6255
$0.69
52주 변동 폭
$0.52
$1.11
Chromocell Therapeutics Corp Stock (CHRO) Company Profile
명칭
Chromocell Therapeutics Corp
전화
(917) 644-6313
주소
685 US HIGHWAY ONE, NORTH BRUNSWICK
CHRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CHRO | 0.63 | 3.75M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Chromocell Therapeutics Corp 주식(CHRO)의 최신 뉴스
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - The Manila Times
Chromocell Therapeutics Corporation Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - Marketscreener.com
Chromocell to Present at Upcoming Fall Investor Conferences - The Manila Times
Chromocell announces amendment to stock repurchase plan - MSN
Chromocell Therapeutics amends stock repurchase plan - TradingPedia
Chromocell boosts stock buyback plan to $750,000 - Investing.com India
Chromocell Announces Amendment to Stock Repurchase Plan - The Manila Times
Chromocell boosts stock buyback plan to $750,000 By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Upward Trajectory: Chromocell Therapeutics Corp. (CHRO) Posts a Slidee, Closing at 0.84 - The Dwinnex
CHRO’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Chubb (CB) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Stocks of Chemours Company (CC) are poised to climb above their peers - SETE News
Chubb Limited [CB] stock was sold by GREENBERG EVAN G at the price of US$8.78 million - Knox Daily
Recent 4.1% pullback isn't enough to hurt long-term Calumet (NASDAQ:CLMT) shareholders, they're still up 373% over 5 years - Yahoo Finance
Calumet Specialty Products Partners (NASDAQ:CLMT) Shares Gap Down to $18.00 - Defense World
Market Update: Calumet Inc. (CLMT) Sees Negative Movement, Closing at 18.00 - The Dwinnex
C.H. Robinson Worldwide Sees Unusually High Options Volume (NASDAQ:CHRW) - MarketBeat
CHRS stock touches 52-week low at $1.01 amid market challenges - Investing.com India
CG Oncology initiated with an Outperform at RBC Capital - TipRanks
Comparing BioLargo (NASDAQ:BLGO) and Chemours (NYSE:CC) - Defense World
Chubb Stock Trading Near 52-Week High: What Should Investors Know? - Yahoo Finance
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Morningstar
Choreo LLC Purchases New Stake in C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) - Defense World
Cosmic CRF shares hit 5% upper circuit on Rs 127-crore order win; details - Business Standard
CorMedix stock soars to 52-week high, hits $7.29 By Investing.com - Investing.com Australia
Investor’s Delight: Calumet Inc. (CLMT) Closes Weak at 18.24, Down -0.27 - The Dwinnex
Analyzing Calumet Inc. (CLMT) After Recent Trading Activity - Knox Daily
Another Delaware Publicly Traded Company Proposes A Nevada Move - The National Law Review
Coherus BioSciences, Inc. (NASDAQ:CHRS) Has Found A Path To Profitability - Simply Wall St
Chubb (CB) Rises Higher Than Market: Key Facts - Yahoo Finance
Chromocell therapeutics CEO buys $5,044 in company stock By Investing.com - Investing.com Canada
Chromocell therapeutics director buys $9.8k in stock - Investing.com
Chromocell therapeutics CEO buys $5,044 in company stock - Investing.com India
Chubb Ltd. stock rises Monday, outperforms market - MarketWatch
Life Sciences Virtual Investor Forum Agenda Announced for September 19th - GlobeNewswire
Chromocell to Participate in Life Sciences Investor Forum September 19th - GlobeNewswire
Calumet Specialty Products Partners (NASDAQ:CLMT) Shares Gap Down to $16.58 - Defense World
Chromocell Therapeutics CEO buys shares worth over $10,000 By Investing.com - Investing.com Australia
Market Recap Check: Calumet Inc. (CLMT)’s Positive Finish at 16.58, Up/Down 10.31 - The Dwinnex
Chromocell Therapeutics CEO buys shares worth over $10,000 - Investing.com
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q2 2024 - MSN
Chromocell announces $250,000 stock repurchase plan By Investing.com - Investing.com Australia
Chromocell Therapeutics announces stock repurchase plan up to $250,000 - TipRanks
Chromocell Therapeutics Co.’s Lock-Up Period Will End on August 14th (NYSE:CHRO) - Defense World
Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet - CNBC
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Benzinga
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga
Chromocell Therapeutics Corp (CHRO) 재무 분석
Chromocell Therapeutics Corp (CHRO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):